0001214659-24-013689.txt : 20240802
0001214659-24-013689.hdr.sgml : 20240802
20240802171601
ACCESSION NUMBER: 0001214659-24-013689
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240802
DATE AS OF CHANGE: 20240802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KAZIMI A J
CENTRAL INDEX KEY: 0001075050
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 241172193
MAIL ADDRESS:
STREET 1: 1207 17TH AVENUE SUITE 103
CITY: NASHVILLE
STATE: TN
ZIP: 37212
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
marketforms-66719.xml
PRIMARY DOCUMENT
X0508
4
2024-07-01
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001075050
KAZIMI A J
1600 WEST END AVE.
SUITE 1300
NASHVILLE
TN
37203
true
true
true
false
Chairman and CEO
1
Common Stock
2024-07-01
5
L
false
E
44
1.47
A
5696055
D
Common Stock
2024-07-02
5
L
false
E
44
1.48
A
5696099
D
Common Stock
2024-07-03
5
L
false
E
54
1.52
A
5696153
D
Common Stock
2024-07-05
5
L
false
E
44
1.50
A
5696197
D
Common Stock
2024-07-08
5
L
false
E
44
1.49
A
5696241
D
Common Stock
2024-07-09
5
L
false
E
44
1.50
A
5696285
D
Common Stock
2024-07-10
5
L
false
E
44
1.50
A
5696329
D
Common Stock
2024-07-11
5
L
false
E
44
1.47
A
5696373
D
Common Stock
2024-07-12
5
L
false
E
27
1.49
A
5696400
D
Common Stock
2024-07-15
5
L
false
E
44
1.48
A
5696444
D
Common Stock
2024-07-16
5
L
false
E
40
1.50
A
5696484
D
Common Stock
2024-07-17
5
L
false
E
14
1.45
A
5696498
D
Common Stock
2024-07-18
5
L
false
E
44
1.48
A
5696542
D
Common Stock
2024-07-19
5
L
false
E
27
1.48
A
5696569
D
Common Stock
2024-07-22
5
L
false
E
44
1.49
A
5696613
D
Common Stock
2024-07-23
5
L
false
E
44
1.50
A
5696657
D
Common Stock
2024-07-24
5
L
false
E
44
1.50
A
5696701
D
Common Stock
2024-07-25
5
L
false
E
34
1.49
A
5696735
D
Common Stock
2024-07-26
5
L
false
E
44
1.50
A
5696779
D
Common Stock
2024-07-29
5
L
false
E
44
1.49
A
5696823
D
Common Stock
2024-07-30
5
L
false
E
14
1.48
A
5696837
D
Common Stock
2024-07-31
5
L
false
E
44
1.45
A
5696881
D
The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2024.
A.J. Kazimi by /s/ John Hamm as attorney-in-fact
2024-08-02